Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q02252
UPID:
MMSA_HUMAN
Alternative names:
Aldehyde dehydrogenase family 6 member A1
Alternative UPACC:
Q02252; B2R609; B4DFS8; J3KNU8; Q9UKM8
Background:
Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial, also known as Aldehyde dehydrogenase family 6 member A1, is a pivotal enzyme in valine and pyrimidine metabolism. It binds fatty acyl-CoA, indicating its essential role in the breakdown and utilization of fatty acids and amino acids within the mitochondria.
Therapeutic significance:
Methylmalonate semialdehyde dehydrogenase deficiency, a metabolic disorder linked to this enzyme, highlights its critical function. Understanding the role of Methylmalonate-semialdehyde dehydrogenase could open doors to potential therapeutic strategies for treating this deficiency and improving metabolic health.